(Q41008161)

English

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

scientific article published on 21 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

25 September 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Julien Mazieres

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Denis Moro-Sibilot

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Christian Creveuil

19

object named as

Christian Creveuil

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Gérard Zalcman

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jacques Margery

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Laurent Greillier

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Olivier Molinier

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Romain Corre

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Isabelle Monnet

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Valérie Gounant

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Frédéric Rivière

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Henri Janicot

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Radj Gervais

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chrystèle Locher

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Bernard Milleron

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Quan Tran

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marie-Paule Lebitasy

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jean-Jacques Parienti

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Arnaud Scherpereel

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

French Cooperative Thoracic Intergroup (IFCT)

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Clarisse Audigier-Valette

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

0 references

publication date

21 December 2015

1 reference

Europe PubMed Central

25 September 2017

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

387

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

10026

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1405-1414

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26719230%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Prognostic factors for mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

What is the survival after surgery for localized malignant pleural mesothelioma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of response classification criteria for patients with malignant pleural mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified RECIST criteria for assessment of response in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple testing in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Improper analysis of trials randomised using stratified blocks or minimisation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trials stopped early for benefit: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901238-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41008161&oldid=2092968729"